Sanaz Soltani, MD

Heme/Onc🩸🧪🥼 | Training:@NCICCR_WMB @NIH_NHLBI @GeisingerHealth | Currently:@WVUcancer | Posts=mine≠employer/endorsement | #HOWPG #Wolfpack #OncTwitter

[Sanaz Soltani, MD @SoltaniMD]

@Alfdoc2 @THilalMD I have an analogy where I compare cancer to a city with surrounding towns and travelers who are trying to find new homes. I tie surgeons to cutting out the city, rad onc to nuking the towns, and me (medonc) to poisoning the travelers in hopes they don’t find new homes

[Sanaz Soltani, MD @SoltaniMD]

Cool

[David Steensma, MD @DavidSteensma]

#HematologyTweetstory 32: lymph nodes with names. There’s also a major personal announcement in this thread. We each have lots of lymph nodes: an estimated 500-600 (Image: @MayoClinic). Like stars, they cluster. (Did you ever think of your axilla as a lymphatic “galaxy”?)🙂/1

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

#ASCO22 is only 2 weeks away! Below are my Top 10 abstracts I'm looking forward to in #bcsm across early & metastatic settings.

I've also attached the "why" - what is intriguing me about these particular abstracts or why they are important IMO.

@SarahCannonDocs @OncoAlert

[Yüksel Ürün @DrYukselUrun]

APHINITY: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive #breastcancer

"Age per se is not a reason either to prescribe more aggressive therapies or to expect a different treatment benefit" ~IDFS for age ≤40 or >40

@JNCI_Now @OncoAlert
https://t.co/i1mCk2TFkr

[Sanaz Soltani, MD @SoltaniMD]

@Dr_RShatsky

[Christopher Melani @MelanicjMD]

Great talk by my colleague and co-mentor @RoschewskiMD from @NCICCR_Lymphoma on a novel trial with Acala window in 1L DLBCL. Responses to BTKi across all COO and LymphGEN subtypes with ctDNA showing an early indicator of radiographic response #ASH21 #lymphoma

[Sara Tolaney @stolaney1]

EBCTCG analysis of taxane with and w/o anthracycline. 15% relative reduction and 2.5% absolute reduction in invasive recurrence for A+T vs T. Larger reduction with concurrent schedules.

@OncoAlert #SABCS2021 #bcsm

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news: Triplet therapy with Darolutamide + Docetaxel + ADT improves OS compared to docetaxel + ADT in men with mCSPC #ProstateCancer👉Significantly improved OS, the primary endpoint. Another position triplet Rx trial after Peace-1. @OncoAlert @urotoday

[Leigh Pate @LPseattle]

👉"I think FES-PET/CT may change patient management for initial staging of ER+ #lobular #breastcancer"👈 Early results look promising! Thx Dr. Covington @huntsmancancer
#bcsm @ASTRO_org @ASCO @RadiologyACR @radiology_rsna @AuntMinnie
https://t.co/xf4xWaJBjR

[Sanaz Soltani, MD @SoltaniMD]

This thread 🥺

[Londyn Robinson, MD @londyloo]

I lost my mentor. Pat Carlson, who as a rheum study coordinator hired me at 17 yo when I came from rural small town, who signed me up for mcat, who gave me $ for apps when I couldn’t afford secondaries, cried on my wedding and divorce day. 1/2

[Mark Lewis, MD, FASCO @marklewismd]

I’ve never seen a better graphical depiction of grief

[Ravi A Madan M.D. @Dr_RaviMadan]

Free Self Paced on-line @NIH #Pharmacology course

#pharmacology is very complicated, but necessary for many aspects of #medicine & #research

Learn from a course directed by 2 of the best: Drs. Cordes & Figg @WilliamFigg1

#MedTwitter

Link: https://t.co/kI97dPiif1…

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

#SABCS21 Abstracts are out! Here’s what I’m looking forward too!
⁦@matteolambe⁩ ⁦@OncoAlert⁩ ⁦@ErikaHamilton9⁩ ⁦@JavierCortesMD⁩ ⁦@SABCSSanAntonio⁩ ⁦@DrLoveResearch⁩ ⁦@BrownUCancer⁩

[Sanaz Soltani, MD @SoltaniMD]

@Dr_RShatsky I just bombarded your inbox but if I could like your comments a million times I would. Unless you’ve lived it, you don’t get it. I bit my tongue many times when it came up. Luckily I have worked in very supportive environments

[Sanaz Soltani, MD @SoltaniMD]

@chulkimMD CONGRATS!
Tomorrow is another day though…

[Sanaz Soltani, MD @SoltaniMD]

@DrGattiMays @DrOjemuyiwa Welcome!!!

[Heather Wakelee @HwakeleeMD]

Very happy to see the FDA approval of adjuvant atezolizumab in patients with resected PD-L1+ early stage NSCLC. So excited to have been a part of the practice changing IMpower010 trial! Making a difference in the lives of NSCLC patients! #LCSM

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

FDA Approves Adjuvant Atezolizumab for PD-L1+ Non–Small Cell Lung Cancer ⁦@TargetedOnc⁩ https://t.co/LyiX8kbiXR

[Annals of Oncology @Annals_Oncology]

Abemaciclib + endocrine therapy for early breast cancer was approved by @FDAOncology based on the monarchE study.
Results of the the primary outcome analysis presented at the #ESMOVirtualPlenary are available #openaccess in @Annals_Oncology https://t.co/I5kFGN3NBJ #bcsm

[Matteo Lambertini, MD PhD @matteolambe]

Updated data from #monarchE trial just presented at #ESMOVirtualPlenary showing increased magnitude of benefit for the addition of #abemaciclib to adjuvant #EndocrineTherapy in high-risk HR+/HER2- #BreastCancer patients: very important data!

@myESMO @OncoAlert @Annals_Oncology

[Abeid Athman (Omar). @bin_abeid]

Who are the patients who will benefit the most from abemaciclib in adjuvant ET? What is the optimum duration for CDK 4/6 inhibitors? @dradityabardia @matteolambe @kevinpunie @myESMO @prat_aleix